Death row inmates appeal after botched execution

Image
AFP Washington
Last Updated : May 13 2014 | 5:10 AM IST
Three US death row inmates have filed new appeals seeking to stop their executions citing apparent suffering by a prisoner put to death in a botched procedure in Oklahoma last month.
Robert James Campbell, who is due to die in Texas today, sought a stay on the grounds that he may be subjected to an execution as painful as the one suffered by Clayton Lockett on April 29.
Convicted killer and rapist Lockett died 43 minutes after the start of the lethal injection and appeared to be in significant pain. Lethal injections normally take around 12 minutes.
US states using the death penalty face critical shortages of lethal injection drugs after European firms stopped supplying pentobarbital.
The shortage has prompted many US states to turn to compounding pharmacies to supply untested execution cocktails instead.
Campbell yesterday requested a New Orleans' court's reversal of a denial of the execution stay he has sought.
Mr Campbell's "8th Amendment rights can only be protected if he is provided the information required to ensure a humane, non-torturous execution," his attorney Maurie Levin wrote. The eighth amendment bars "cruel and unusual" punishment.
Russell Bucklew, who is due to receive a lethal injection next week in Missouri, has argued that a vascular tumor and circulatory problems could put him at risk for the kind of suffering witnessed in Oklahoma.
"There is also a grave risk that, because of Mr. Bucklew's severe vascular malformations, the lethal drug will not circulate as intended, delaying the suppression of the central nervous system and prolonging the execution - which will likely cause excruciating pain to Mr. Bucklew," said his attorney Cheryl Pilate.
"These risks are heightened by the use of a compounded drug, pentobarbital, in the absence of any disclosure about the drug's safety, purity and potency. In fact, the Department of Corrections will not even confirm whether the drug is subject to any laboratory testing whatsoever," she said.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 13 2014 | 5:10 AM IST

Next Story